Clinical Outcomes of Poly(ADP–Ribose) Polymerase Inhibitors as Maintenance Therapy in Patients with Ovarian Cancer in the Southeastern Region of Korea
In a real-world setting, PARP inhibitors showed efficacy comparable to that reported in published randomized controlled trials and had acceptable safety profiles.
Authors
- Changho Song (ORCID: https://orcid.org/0000-0001-5530-6419)
- Eun Taeg Kim (ORCID: https://orcid.org/0000-0002-2754-2657)
- Hyeong In Ha (ORCID: https://orcid.org/0000-0002-7045-7976)
- Yong Jin Na (ORCID: https://orcid.org/0000-0001-6842-3139)
- Ki Hyung Kim (ORCID: https://orcid.org/0000-0003-2364-5875)
- Yong Jung Song (ORCID: https://orcid.org/0000-0002-6103-2466)
- Hyung Joon Yoon
- Dong‐Soo Suh
Institutions
- Ulsan College (KR)
- Kosin University Gospel Hospital (KR)
- University of Ulsan (KR)
- Pusan National University Hospital (KR)
- Ulsan University Hospital (KR)
- Pusan National University Yangsan Hospital (KR)
- Pusan National University (KR)
Publication Details
- Journal
- Current Oncology
- Published
- 2024-10-28
- DOI
- https://doi.org/10.3390/curroncol31110495
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pusan National University
- Pusan National University Hospital